This research explores antimiRNA therapy targeting miR-888 and miR-891a to slow aggressive prostate cancer progression, indicating potential clinical benefits.
Key Points
The central aim is to evaluate the effectiveness of targeting miR-888 and miR-891a as potential therapies for aggressive prostate cancer.
Identified miR-888 cluster's role in aggressive prostate cancer using cell lines and human samples.
Developed pHLIP-PNA-antimiRs to enhance delivery to prostate tumors.
Tested effects of pHLIP-PNA-antimiRs on cancer cell growth and nastiness in vitro.
Conducted xenograft studies to assess tumor response in mice treated with pHLIP-PNA-antimiR-891a.
miR-888 and miR-891a levels were significantly higher in castration-resistant prostate cancer cell lines.
pHLIP-PNA-antimiR treatment reduced cancer cell growth significantly, especially in aggressive cell lines like PC3-ML.
In xenograft models, treatment with antimiR-891a decreased tumor volume in mice.